Anna Ruiz-Llobet

Dr. Anna Ruiz-Llobet

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ARAnna Ruiz-Llobet
Anna Ruiz-Llobet
SRSusanna Gassiot Riu
Susanna Gassiot Riu
ESEdurne Sarrate
Edurne Sarrate
JZJosune Zubicaray
Josune Zubicaray
JDJosé Luis Dapena
José Luis Dapena
BRBerrueco Rubén
Berrueco Rubén

23 April 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
YGYari Giménez
Yari Giménez
MPManuel Palacios
Manuel Palacios
RSRebeca Sánchez-Domínguez
Rebeca Sánchez-Domínguez
CZChristiane Zorbas
Christiane Zorbas
JPJorge Peral
Jorge Peral
SNSusana Navarro
Susana Navarro
This study lays the groundwork for future lentivirus-mediated gene therapy in patients with Diamond Blackfan anemia (DBA) caused by mutations in ribosomal protein S19 ( RPS19 ), showing evidence of a new safe and effective therapy. The data show that, unlike patients with Fanconi anemia (FA), the hematopoietic stem cell (HSC) reservoir of patients with DBA was not significantly reduced, suggesting that collection of these cells should not constitute a remarkable restriction for DBA gene therapy. Subsequently, 2 clinically applicable lentiviral vectors were developed. In the former lentiviral vector, PGK.CoRPS19 LV , a codon-optimized version of RPS19 was driven by the phosphoglycerate kinase promoter ( PGK ) already used in different gene therapy trials, including FA gene therapy. In the latter one, EF1 α .CoRPS19 LV , RPS19 expression was driven by the elongation factor alpha short promoter, EF1 α (s) . Preclinical experiments showed that transduction of DBA patient CD34 + cells with the PGK.CoRPS19 LV restored erythroid differentiation, and demonstrated the long-term repopulating properties of corrected DBA CD34 + cells, providing evidence of improved erythroid maturation. Concomitantly, long-term restoration of ribosomal biogenesis was verified using a potentially novel method applicable to patients’ blood cells, based on ribosomal RNA methylation analyses. Finally, in vivo safety studies and proviral insertion site analyses showed that lentivirus-mediated gene therapy was nontoxic.

Verified
Journal Article
Open access
PDF file
JAJosé Manuel González De Aledo-Castillo
José Manuel González De Aledo-Castillo
AAAna Argudo-Ramírez
Ana Argudo-Ramírez
DBDavid Beneitez-Pastor
David Beneitez-Pastor
AGAnna Collado Gimbert
Anna Collado Gimbert
FCFrancisco Almazán Castro
Francisco Almazán Castro
OCon behalf of the Sickle Cell Disease Newborn Screening Group of Catalonia
on behalf of the Sickle Cell Disease Newborn Screening Group of Catalonia
In 2015, Catalonia introduced sickle cell disease (SCD) screening in its newborn screening (NBS) program along with standard-of-care treatments like penicillin, hydroxyurea, and anti-pneumococcal vaccination. Few studies have assessed the clinical impact of introducing NBS programs on SCD patients. We analyzed the incidence of SCD and related hemoglobinopathies in Catalonia and the change in clinical events occurring after introducing NBS. Screening 506,996 newborns from 2015 to 2022, we conducted a retrospective multicenter study including 100 screened (SG) and 95 unscreened (UG) SCD patients and analyzed SCD-related clinical events over the first six years of life. We diagnosed 160 cases of SCD, with an incidence of 1 in 3169 newborns. The SG had a significantly lower median age at diagnosis (0.1 y vs. 1.68 y, p < 0.0001), and initiated penicillin prophylaxis (0.12 y vs. 1.86 y, p < 0.0001) and hydroxyurea treatment earlier (1.42 y vs. 4.5 y, p < 0.0001). The SG experienced fewer median SCD-related clinical events (vaso-occlusive crisis, acute chest syndrome, infections of probable bacterial origin, acute anemia requiring transfusion, acute splenic sequestration, and pathological transcranial Doppler echography) per year of follow-up (0.19 vs. 0.77, p < 0.0001), a reduced number of annual emergency department visits (0.37 vs. 0.76, p < 0.0001), and fewer hospitalizations (0.33 vs. 0.72, p < 0.0001). SCD screening in Catalonia’s NBS program has effectively reduced morbidity and improved affected children’s quality of life.

29 April 2024 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ARAnna Ruiz-Llobet
Anna Ruiz-Llobet
SGSusanna Gassiot
Susanna Gassiot
ESEdurne Sarrate
Edurne Sarrate
JZJosune Zubicaray
Josune Zubicaray
SRSusana Rives
Susana Rives
BRBerrueco Rubén
Berrueco Rubén
Background Venous thromboembolism (VTE) etiology in children with acute lymphoblastic leukemia (ALL) is multifactorial. The use of global assays of hemostasis as a thrombin generation test (TGT) is useful to individualize VTE risk in adult patients. This prospective cohort study aimed to evaluate the usefulness of an automated TGT to evaluate VTE risk during ALL treatment in children. Methods TGT (automated analyzer ST Genesia; ThromboScreen) and pro- and anticoagulant plasma proteins were analyzed during ALL treatment in pediatric patients following LAL-SEHOP-PETHEMA-2013 guidelines. Results were compared with a series of pediatric normal controls and evaluated according to pegylated asparaginase PEG-ASP administration and to VTE risk factors. Results The study included 67 patients: males n = 35, B-ALL (n = 60). None had a VTE during the evaluated period. Compared to healthy controls, the normalized endogenous thrombin potential (N-ETP) ratio in patients was higher and ETP inhibition (ETP-inh) was lower, especially after PEG-ASP administration. Plasmatic protein C and protein S levels decreased after PEG-ASP administration, but antithrombin mean level did not. A bivariant analysis showed that ETP-inh was lower in patients >10 years old (p = 0.05) and in those with non-O blood type (p = 0.005). A linear mixed model also showed a higher TGT prothrombotic profile in patients with inherited thrombophilia. Conclusion TGT could be a biomarker of a high VTE risk in ALL pediatric patients. Non-O blood group and inherited thrombophilia were associated with a significantly higher thrombotic profile, and an increased profile was also observed after administration of PEG-ASP.